Conexeu Sciences INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Conexeu Sciences announced the completion of its 12-month P.R.O.O.F preclinical study for its CXU platform, demonstrating tissue restoration and injectable performance, paving the way for a planned 510(k) submission in wound care by Q1 2027.